Content
04/02/2024
Atlanta, GA USA
EarliTec Diagnostics
completed $21.5 million Series B Round funding. Investors include
Venture Investors (lead), Nexus NeuroTech Ventures (lead).
About
EarliTec Diagnostics is making earlier identification and treatment for autism and related early childhood vulnerabilities accessible to children everywhere. EarliTec's flagship product, EarliPoint™, is FDA authorized to diagnose and assess autism in children ages 16-30 months old and is available now.
Startup
Sector:
Healthcare
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
